intermediate dose Enoxaparin/ unfractionated heparin — Competitive Intelligence Brief

intermediate dose Enoxaparin/ unfractionated heparin (intermediate dose Enoxaparin/ unfractionated heparin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Low molecular weight heparin. Area: Cardiovascular.

phase 3 Low molecular weight heparin Antithrombin Cardiovascular Small molecule

Target snapshot

intermediate dose Enoxaparin/ unfractionated heparin (intermediate dose Enoxaparin/ unfractionated heparin) — Rajaie Cardiovascular Medical and Research Center. Enoxaparin and unfractionated heparin work by inhibiting the coagulation cascade, specifically by activating antithrombin and inhibiting thrombin and factor Xa.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
intermediate dose Enoxaparin/ unfractionated heparin TARGET	intermediate dose Enoxaparin/ unfractionated heparin	Rajaie Cardiovascular Medical and Research Center	phase 3	Low molecular weight heparin	Antithrombin
Lovenox (Preservative Free)	ENOXAPARIN SODIUM	Sanofi	marketed	Low Molecular Weight Heparin	Antithrombin-III	1993-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anticoagulant	Antithrombin III, Coagulation Factors Xa and IIa	1939-01-01
Heparin Sodium In Plastic Container	HEPARIN	Merck & Co.	marketed	Anti-coagulant	Antithrombin-III	1939-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anticoagulant	Antithrombin III; Coagulation Factors Xa and IIa	1939-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anti-coagulant	Antithrombin III, Factor Xa, Factor IIa	1939-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anticoagulant	Antithrombin III, Coagulation Factors Xa and IIa	1939-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Low molecular weight heparin class)

1. Aalborg University Hospital · 1 drug in this class
2. Queen Mary University of London · 1 drug in this class
3. Rajaie Cardiovascular Medical and Research Center · 1 drug in this class
4. VarmX B.V. · 1 drug in this class